Exalenz Bioscience Launches its BreathID(R) Breath Test System for Point-of-Care Detection of H. pylori in the USA
MODI'IN, Israel, Jan. 21 /PRNewswire/ -- Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
The BreathID® System is a breath test platform capable of analyzing parts-per-million changes in carbon 13 and carbon 12 ratios in a patient's breath. Exalenz offers physicians two distinct offerings. The first is the Hp FasTest™, which is an in-office testing platform performed using a dedicated BreathID® device that is located in the physician's office. With this option, H. pylori testing can be done on the spot with results received in around 10 minutes. The second option is the Hp BagTest™, a send-in service which will be available in certain states. With this, collected breath samples will be sent to a dedicated breath testing center for analysis, and the results will be reported to the physician within a few days. The first Breath Test Center will be established in cooperation with Metabolic Solutions Inc. that has 20 years experience in analyzing breath test samples.
According to Steven Eitan, CEO of Exalenz: "The BreathID® is an exciting solution, enabling physicians to offer excellent care to patients. Its ability to detect H. pylori in patients presenting H. pylori related symptoms is an important addition to any physician's office or clinical laboratory."
Exalenz Bioscience specializes in the diagnosis and monitoring of gastroenterological and liver related diseases, using its proprietary BreathID® Breath Test platform. For additional information, logon to the Company's website: www.exalenz.com and to the new website dedicated to the H. pylori field: www.helicobacterpyloritest.com.
Statements in this release of future expectations, plans and prospects may include forward-looking statements. The Company's actual results, performance and execution may differ materially from those discussed, based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, risks associated with competition and competitive pricing pressures and economic conditions generally.
For more information, please call Dennis Boyle at 1-888-EXALENZ or email email@example.com.
SOURCE Exalenz Biosciences